Real-Life Effectiveness and Safety of Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A Single-Center 16-Week Study.
Luigi GargiuloLuciano IbbaAndrea CorteseJessica AvaglianoMario ValentiAntonio CostanzoAlessandra NarcisiPublished in: Dermatology and therapy (2023)
We observed higher rates of EASI75/EASI90/EASI100 responses at week 16, compared with data from clinical trials. The safety profile of upadacitinib was favorable, as no AEs leading to discontinuation were experienced by our patients up to week 16.
Keyphrases
- clinical trial
- end stage renal disease
- atopic dermatitis
- ejection fraction
- chronic kidney disease
- young adults
- newly diagnosed
- physical activity
- peritoneal dialysis
- prognostic factors
- placebo controlled
- randomized controlled trial
- big data
- patient reported outcomes
- patient reported
- study protocol
- double blind
- drug induced
- data analysis